BTS Research Appoints Mark Crane as Vice President, Business Development
BTS Research, a preclinical services Contract Research Organization, is delighted to announce the addition of Mark T. Crane as Vice President of Business Development. Mark will be taking on the Company’s Marketing, Sales, and Business Development efforts pushing BTS’s business growth model and fostering positive relationships with new and current clients. Particularly, Mark will be pushing BTS’s Toxicology capabilities that aid in the regulatory approval of clients’ drug developmental programs including GLP studies.
Crane joins BTS Research from Sinclair where he served as Vice President of Business Development and Marketing. He has held similar positions at SNBL, Ricerca Biosciences, Bridge Pharmaceuticals, ITR, Quest Pharmaceutical Services and MDS Pharma Services.
Crane’s extensive expertise in management, business development and marketing in the preclinical market will be of significant value to the BTS team and the clients. He has an excellent track record of growing preclinical business at exceptional rates.
“Mark’s combination of industry knowledge, sales training and management skills will enable BTS to move to the next level in size, scope and market leadership,” said Sami Abunadi, President & CEO of BTS Research. “Since 2011, BTS has seen double digit growth in their Toxicology offerings year after year and has reached a point where a seasoned industry expert is needed to groom and foster this growth. As a well-recognized industry executive, Mark has proven leadership skills that will be invaluable as we continue to grow our business and add key contributors to the management team.”
About BTS Research
BTS Research provides in vivo and in vitro preclinical research for pharmaceutical, biotechnology and medical device industries worldwide. As both a GLP and non-GLP CRO with extensive experience in discovery research models through IND enabling developmental studies, BTS provides clients with valuable research, direction, best practices and regulatory compliance requirements which ultimately helps them in achieving their goals. BTS is considered instrumental in bettering the lives of humans and animals and is instrumental in value creation for its partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181114006008/en/